AUTHORS
Julie Kanter, MD, Najibah Galadanci, PhD, MBBS, MPH2, Vinal Menon3, Jane A Little, MD4, Sophie Lanzkron, MD, MHS5
AFFILIATIONS
1 University of Alabama at Birmingham, Birmingham, Alabama, United States
2 University of Alabama at Birmingham, Birmingham, Alabama, United States
3 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
4 University of North Carolina, Chapel Hill, North Carolina, United States
5 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
ABSTRACT
Background:
Sickle cell disease (SCD) is a genetic disorder characterized by acute painful crisis (APC), vaso-occlusion, organ damage, and early mortality for which there are limited disease-modifying therapies. Randomized placebo-controlled trials (RCT) using the number of APC’s as an endpoint is the current gold standard for developing new pharmaceuticals for SCD. The focus on acute pain as an endpoint limits eligibility to people with SCD with frequent history of APC in the prior 12 months and often excludes people who may have organ damage, debilitating fatigue, or other common SCD complications. We examined the National Alliance of Sickle Cell Center’s Globin Regional Network for Data and Discovery (GRNDaD) Registry to assess the applicability of current eligibility criteria used in clinical trials in a large, unselected population. GRNDaD is an IRB approved, prospective, multicenter clinical registry which uniquely combines SCD phenotype, clinical manifestations, laboratory assessments and patient reported outcomes.
Aims: To assess the generalizability of commonly used eligibility criteria in contemporary clinical trials for SCD in a real-world setting using the GRNDaD registry.
Methods: A keyword search of ClinicalTrials.gov was conducted to identify active/recruiting industry-sponsored clinical trials (CT) for SCD to assess their eligibility criteria. The most common inclusion criteria were age 16-55 years, hemoglobin (hb) 5.5-10.5g/dl, APC of 2-12 in the prior 12 months. Most CT require steady-state use of disease modifying therapies though some of the CT precluded the use of hydroxyurea and/or crizanlizumab. All CT excluded patients on chronic red cell transfusion (CRCT). Exclusion of persons with chronic renal or liver dysfunction and a history of overt stroke was also common. Using these inclusion/exclusion criteria, a static query of active persons in the GRNDaD registry was performed to identify the percentage of patients that would be eligible for these CT.
Results: There were 6856 persons in GRNDaD from 70+ centers at the time of this assessment. The query was restricted to living persons with complete minimum data resulting in 4,912 unique subjects (54% females, median age of 25 years (range 2-88) 62.5% with HbSS disease). Consistent with most of the current CT, we selected adults 18-55 years resulting in 2,814 individuals. When applying the Hb restrictions (baseline (non-acute) hb of 5-10.5g/dl), there were 1597 persons remaining. We then excluded subjects with a history of overt stroke (n=280) or who were receiving CRCT (n=365) or were status post stem cell transplant (n=8), resulting in 944 potential subjects The cohort was then restricted to people who experienced 2-12 APC in the prior 12 months which resulted in a final eligible population for clinical trials to only 288 people (5.9% of the active GRNDaD cohort). Of note, 2 CT for SCD further restrict enrollment by excluding persons taking hydroxyurea, which would restrict the eligible pool to 63 persons, or 1.3% of the cohort.
Conclusions: People with SCD have few treatment options and face significant morbidity caused by multi-organ complications, anemia and painful episodes. The results from this study illustrate how the current focus on APC (as currently defined) as an endpoint significantly limits enrollment to <10% of the people with SCD in the GRNDaD Registry; thereby excluding ~90% of real-world adults from participation. Of concern is that the resulting evidence base and corresponding product labeling does not adequately reflect the population most likely to receive these therapies in clinical care. Furthermore, confirmatory phase IV trials and off-label use of these therapies may lead to detrimental results (as we have seen), including unexpected side effects (or death) and/or the withdrawal of therapies that may have been very effective for a subset of people but caused harm to others.
With limited available treatments and recent failures, SCD urgently needs new endpoints and CT designs. In a rare disease population, the use of randomized CT may not sufficiently expose the clinical heterogeneity of a patient population to the product. New trial designs need consideration including the use of external controls, responder-based analyses, and pre-post models. Continued development of safe, effective, and accessible therapies is essential to reduce morbidity, and improve survival and quality of life, for individuals living with SCD.
DISCLOSURES
Julie Kanter, MD: NIH - Research Funding; Sanofi - Research Funding; CDC - Research Funding; HRSA - Research Funding; BMS - Research Funding; Novo Nordisk - Research Funding; Beam Therapeutics - Research Funding; Terumo - Research Funding; Beam Therapeutics - Consultancy (Includes expert testimony); Disc Therapeutics - Consultancy (Includes expert testimony); Octapharma - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Fulcrum - Consultancy (Includes expert testimony); Gamida Cell - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Nuvamid - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Agios - Consultancy (Includes expert testimony); Abt - Consultancy (Includes expert testimony)